OptiBiotix Health (LSE:OPTI) has secured four major orders totalling 24 metric tonnes of its flagship weight management ingredient SlimBiome from Taiwanese distributor Meelung Trading, marking its largest set of early-year commitments to date. The orders, which will be delivered in phased shipments across 2026, reflect strong sales momentum since the two companies entered into a distribution agreement in mid-2025.
Including these contracts, a previously announced low six-figure order from a leading weight management company, and commitments from two additional partners, OptiBiotix has now secured more than £800,000 of non-cancellable orders early in the year. Management said this provides improved revenue visibility, greater supply-chain efficiency and enhanced pricing leverage as the business scales.
The company is positioning SlimBiome within the fast-growing market for natural alternatives to GLP-1-based weight management solutions. Its clinically supported efficacy and regulatory claims are seen as key differentiators, strengthening OptiBiotix’s competitive position as it enters 2026 with growing commercial traction.
Despite this progress, the broader investment outlook remains mixed. Ongoing losses and cash outflows continue to weigh on sentiment, while technical indicators point to a sustained downtrend in the share price. Although the group remains debt-free, valuation support is limited by negative earnings and the absence of a dividend.
More about OptiBiotix Health
OptiBiotix Health plc is a UK-listed life sciences group focused on developing microbiome-based technologies and products aimed at preventing and managing human disease. Its portfolio includes functional and prebiotic ingredients such as SlimBiome, WellBiome, SweetBiotix and Microbiome Modulators, alongside skincare interests through SkinBioTherapeutics and probiotics via ProBiotix Health, targeting high-growth global consumer health and weight management markets.
Leave a Reply